This study reports the outcome of in situ aortic reconstruction using cryopreserved allografts. It emphasizes the need for close postoperative surveillance because of the substantial early graft-related complication rate. It studies the influence on allograft behavior of two cryopreservation protocols generally reported and used in this series. It also identifies five independent predictors of early mortality: age, chronic kidney disease, coronary disease, prosthetic infection, and urgent procedures.
INTRODUCTION
The incidence of infected aortic aneurysms, commonly referred to as "mycotic aneurysms" is low and reported to vary from 0.6 to 3.0% of all aneurysms, occurring throughout the aorta, with 50% in the infrarenal position. 1 Vascular graft infection occurs after 0.2e6.0% of interventions. 2, 3 All surgical options share the same principle: to perform radical treatment by excising the infected tissues and material, and to re-establish arterial continuity. Extraanatomical reconstruction associated in a simultaneous or staged manner with in situ debridement has been long regarded as a reference method. However, in the last decade, reinfection rates and stump pathology have led to growing consideration of in situ replacement using different materials. Cryopreserved arterial allografts offer the advantages of experimental 4, 5 The aim of this study was to assess the outcome and complications of patients treated with cryopreserved arterial allografts for aortic graft infections and infected aortic aneurysms based on a single center experience.
METHODS
A retrospective review of a prospectively maintained database from September 2004 to June 2012 was conducted. Patients who underwent in situ cryopreserved arterial allograft implantation for a native or prosthetic aortic infection at the Henri Mondor University Hospital were identified. The patient list was crosschecked using the database of the tissue bank that provided the allografts.
Diagnosis was based on clinical and biological findings combined with computed tomography. Specimens for microbiological cultures were obtained before surgery (blood culture and local specimen from infected wounds) and appropriate antibiotic therapy was prescribed accordingly.
Total removal of the infected graft or aortic tissues was performed whenever possible. Tissue samples were obtained for microbiological cultures. The remaining bed was thoroughly irrigated with povidone iodine standard solution diluted in 0.9% isotonic NaCl. Whenever possible, the allograft was covered with a pedicled anterior omentoplasty. Digestive fistulae were treated with the help of visceral surgeons.
Allograft management
Allografts were harvested from brain deceased multiple organ donors. Donor serum samples were screened for HIV-1 and HIV-2 antibodies (p24 antigenemia, HIV RNA polymerase chain reaction [PCR] test), human T-lymphocyte virus 1 and 2, hepatitis B virus (RNA PCR test, hepatitis B antigenemia, antiHBc antibodies), hepatitis C virus (anti-hepatitis C antibodies, RNA PCR) and syphilis. Bacteriological controls were performed on the liquid storage medium. The sterility of the graft was confirmed by cultures for bacteria and fungi.
After being rinsed with the heparinized saline solution, the allografts were immersed in the cold (4 C) transfer medium, which was composed of 0.9% sodium chloride and 0.2% glucose (pH 6.8) without antibiotics. The arterial allografts were stored at 4 C in SCOT solution (Macopharma Laboratories, Tourcoing, France) containing gentamicin (50 mg/mL), clindamycin (600 mg/mL), and vancomycin (500 mg/mL), and cryopreserved within 48e72 hours. They were transferred into freezing bags (Hemofreeze bag Z2012; Fresenius HemoCare, L'Arbresue, France). Cryopreservation solution (100 mL) was added.
Between 1998 and 2002, the cryopreservation solution was composed of 90 mL of a 4% human serum albumin solution and 10 mL of dimethyl sulfoxide (DMSO). After 30 minutes of equilibrium at 4 C, the bags were placed in a controlled rate liquid nitrogen freezing chamber (Planer, Sunbury-on-Thames, UK) and frozen at a cooling rate of À1 C/minute to À50 C, and À5 C/minute from À50 C to À140
C. The frozen grafts were then stored in the vapor phase of liquid nitrogen until use. On the day of transplantation, frozen arteries were rapidly thawed in a 40 C water bath. After removal of the cryoprotectant, the graft was suspended in 100 mL of 0.9% sodium chloride containing 0.2% glucose.
Since 2002, allografts have been permeated for 20 minutes at 4 C in SCOT solution containing 15% DMSO and subsequently frozen at À80 C without rate-controlled freezing, and stored for a maximum of 2 years. At the request of the vascular surgeon, the bag containing the artery remained at room temperature in the operating room for exactly 10 minutes. It was then thawed in prewarmed water (37 C). Afterwards, the allografts underwent successive washouts in heparinized solution at room temperature. The final washout fluid was sampled for bacteriology culture.
Broad-spectrum intravenous antibiotics were administered during the operation and the early postoperative period, and replaced by oral therapy according to the bacteriological results. Oral antibiotics were administered for 4e6 weeks.
Statistical analysis
A descriptive analysis was performed using mean AE SD or median (interquartile ranges) for continuous variables. For categorical variables, absolute numbers and percentages were computed.
Survival analysis. The primary endpoint was the survival rate, considering two events: death (overall survival) and a composite event defined as death or the occurrence of a postoperative complication (event-free survival). The secondary endpoints were the reintervention rate, the limb salvage rate, the reinfection rate, and the graft patency rate.
Patient survival rates were determined using the Kaplane Meier method.
The prognostic significance of potential variables was first determined by means of univariate survival analysis (log rank test): all variables yielding p-values <.20 were then integrated into a multivariate analysis to adjust for possible confounders, using a Cox proportional hazard regression. The Cox regression used a backward stepwise selection method with a significance criterion set at .05 for inclusion in the model, with non-significant variables being removed at each step of the selection. The association of each variable with the outcome was estimated with hazard ratios (HRs) and associated confidence intervals (CIs). Statistical significance was assumed at p < .05; all reported p-values were two-sided.
All statistical analyses were performed with Stata version 11.0 (StataCorp, College Station, TX, USA). Hospital. Overall, 1,520 open and endovascular aortic procedures were performed during the study period.
RESULTS

Fifty
The infected segment was the abdominal aorta in 52 cases and thoracic aorta in two.
Of the 37 prosthetic infections, four (11%) involved aortic stent-grafts, and 33 (89%) occurred on prosthetic grafts. Among those, seven patients presented with aorto-enteric fistula.
The mean interval from the aortic graft placement to the diagnosis of aortic infection was 49.3 months (range 0.34e 324.0 months).
The preoperative characteristics and clinical presentation of the patients are listed in Table 1 .
Allograft reconstruction was performed as an emergency procedure in 12 patients (22%) because of ruptured mycotic aneurysm (n ¼ 4); acute bleeding (n ¼ 4), including three gastrointestinal bleeds through the aorto-enteric fistula; acute limb ischemia (n ¼ 2); and painful mycotic aneurysm (n ¼ 2). In two patients presenting with mycotic aneurysm rupture, initial urgent endovascular exclusion was performed, and then allograft reconstruction was planned. The remaining 42 patients underwent elective surgery (78%).
Operative details
A retroperitoneal approach was used in 17 patients and a transperitoneal approach was used in 34 patients. A posterolateral thoracotomy was performed in two patients, and a bilateral subcostal approach in one. Complete removal of the infected tissues was possible in 89% of patients. Suprarenal cross-clamping was performed in 21 cases (39%), including eight (15%) supraceliac clamp localizations.
Allograft reconstruction types were distributed as follows: aorto-aortic (n ¼ 10), aorto-aortic with visceral and renal artery reimplantation (n ¼ 4), aorto-bi-iliac (n ¼ 11), aorto-bifemoral (n ¼ 21), aorto-unifemoral (n ¼ 6), and aorto-uniiliac (n ¼ 2).
Thirty-three patients (61%) received grafts that had been preserved at À80 C, while 21 (39%) received grafts that were treated and preserved at À150 C according to the classic protocol.
Bacteriological cultures of intraoperative samples were positive in 33 patients. The incriminating microorganisms are shown in Table 2 .
Intraoperative complications and their management are reported in Table 3 .
The early postoperative course
The early mortality rate (i.e., prior to day 30) was 28%. Two patients had suffered from native aortic infection. The 13 other early dying patients were from the group who had prosthetic graft infection (10 prosthetic grafts, three stentgrafts), including four patients with aortoenteric fistulae.
Causes of early mortality were acute bleeding in four patients (one digestive bleeding, two anastomotic disruptions, one intraoperative bleeding), multi-organ failure in four (including three ischemic colitis), acute respiratory distress syndrome in two, septic shock in two, and cardiac failure and pulmonary embolism in one patient each. One patient died suddenly after transfer to the referring hospital, without clear etiology.
Significant early postoperative complications occurred in 28 (52%) patients (Table 4 ). In 10 (19%) patients the complication was directly related to the graft (two anastomotic disruptions, four allograft body disruptions, three allograft leg/branch thromboses and one allograft leg dissection). Four of these patients died from causes directly related to the graft, bringing the graft-related mortality rate to 7%. Nineteen (35%) patients required 34 urgent reoperations: seven intestinal resections, 14 hemostasis maneuvers, 10 revascularization procedures, one nephrectomy, one vena cava thrombectomy, and one thoracic endograft placement.
One amputation was performed during the first postoperative month, and none during the follow-up period. Thus, the limb salvage rate was 97%.
Early and late graft patency rate
There were six early allograft occlusions, always occurring on branches (iliac limbs, renal bypass).
Among the patients who survived the early postoperative period, two (5%) suffered from allograft branch occlusion leading to additional bypass at 6 months in one case, and medical management in the second case.
Reinfection rate
Two patients developed obvious signs of reinfection at days 45 and 63 respectively. Both presented with aortic pseudoaneurysm around the proximal anastomosis with signs of systemic infection. The first patient died from acute respiratory distress syndrome before reoperation could be performed. The second patient had an aortoenteric fistula. The reintervention consisted of an extra-anatomic bypass, but the patient died from severe coagulation disorders.
Late outcomes
Three patients died at days 33, 45, and 70, respectively, before discharge, bringing the in-hospital mortality rate to 33%.
Three patients died during the follow-up period, after discharge, in postoperative months 2, 10, and 33, respectively. The first death was related to treatment, with an outbreak of new aortic pseudoaneurysm, as described above. The two remaining deaths were not related to treatment.
The overall mortality rate in the mycotic aneurysm group was 18%, while it reached 49% in the prosthetic infection group, including the seven patients who presented with aortoenteric fistulae, five of whom died during hospitalization.
No late degenerative change of the allograft was observed during follow-up.
Survival analysis
The median follow-up period for surviving patients was 12.1 months (range 0.4e83.6 months). The mean follow-up was 19.8 months. The overall mortality rate was 39% (21 of 54 patients). The rate of mortality or postoperative complications over the study period was 55% (31 patients), with a median overall and complication-free survival of 1.5 months (95% CI 0.9e9.4).
KaplaneMeier survival curves for overall survival and event-free survival are shown in Fig. 1 . 
Prognostic factors for postoperative complication or mortality (event-free survival)
Univariate analysis identified five factors associated with mortality or postoperative complication: age, diabetes, chronic kidney disease, early revision surgery, and, age of allograft. Multivariate analysis identified age (HR 2.8, 95% CI 1.6e4.9) and chronic kidney disease (HR 3.4, 95% CI 1.2e 9.6), as independent predictors of postoperative death or complication.
Neither allograft age nor cryopreservation protocol were independent prognostic factors in the multivariate analysis. The presence of an aortoenteric fistula appears to be correlated with early death only in univariate analysis (p ¼ .04). In particular, stent-graft infection was not correlated with a negative outcome (p ¼ .23). The relationship between cryopreservation protocol and the occurrence of graft-related complications was tested: two (18%) patients who received the À150 C protocol and six (18%) patients who received the À80 C protocol developed a graft-related complication. The difference was not significant (Fisher's test p-value ¼ 1.0).
DISCUSSION
Many therapeutic options address aortic infections. On account of considerable early mortality (up to 27% 7, 8 ) and issues such as bypass infection (8e27% 7e9 ), and aortic stump or prosthetic rupture (9e15%), extra-anatomical bypass is no longer considered the treatment of choice. Any alternative technique, especially in situ reconstruction, is supposed to achieve a better mortality, patency, and reinfection rate.
The expected benefits of cryopreserved allografts are numerous: better applicability than autologous tissues, shortening of the duration and magnitude of the intervention when harvesting veins, and a reduction in the reinfection rate. This study highlights the following: a high early mortality and graft-related complication rate; the significant predictive value of age, impaired renal function, coronary disease, urgent procedure, and prosthetic infections; the equivalent early behavior of allografts, whether preserved at À80 C or after controlled-rate freezing at À150 C, independently of the graft age.
Mortality
In this series, early postoperative mortality reaches 28%. This value is greater than reported in series published during the last decade where mortality ranges from 18% to 22%; 6,9e11 in the experience of Bisdas et al., it even falls to 9%. 12 The characteristics of the patients in this study are comparable with those included in the other studies discussed. In this study, the suprarenal clamping rate reached 39%, which is comparable with the series of Kieffer et al. (38%), 6 without it being a significant risk factor of mortality. The bacteriological data obtained in this study are close to the spectrum generally reported, with a predominance of Staphylococcus aureus (34.4%). When this series is compared with the study reported by Bisdas et al., 12 which had a similar number and type of patients, and a significantly lower early mortality rate, a few differences should be highlighted: homografts were stored in the vapor phase of liquid nitrogen and were impregnated with neomycin, and only 20% of mycotic aneurysms were ruptured at presentation.
A previous study, performed when the regular use of cryopreserved arterial allografts began, reported a 30-day mortality rate of 22%.
Early and late graft-related complications
In 10 patients (19%), early complications were related to the graft (rupture, thrombosis, dissection). Nonanastomotic mid-graft rupture occurred in four patients with high-risk infections (two aorto-enteric fistulae, two infections with Gram-negative bacteria) and were seemingly related to a local virulent infectious process. That cryopreservation induces allograft fragility is another hypothesis. In the series by Noel et al., 10 26% of patients had allograft-related early complications. This rate falls to 7% and even 0% in other series. 12, 13 Among the 179 patients reported by Kieffer et al., 6 36 underwent 42 (20%) revisions, of which eight (19%) were related to the use of allografts, the majority being fresh allografts. The high rate of early graft-related complications seen in the study appears to be the main impediment to the utilization of cryopreserved allografts. The historical impediment to the use of allografts has been the late degenerative change and is actually curbed by the abandonment of the use of fresh allografts and the avoidance of thoracic segments, both of which are prognostic factors for late events. 6 Such lesions can generally be addressed by minimally invasive endovascular procedures.
14 Their rate of occurrence is low, ranging from 0% to 10%, 9,12e14 but caution is still required because longer follow-up is needed. In this report there were two graft occlusions and no graft dilations.
Alternative reconstruction material
During the study period, the policy was to perform systematic in situ allograft replacement, the tissue bank being part of the Henri Mondor University Hospital. Thus, there were few reconstructions using alternative materials or first-intention extra-anatomical bypass.
In the series of Batt et al., 15 silver-coated graft usage is associated with a perioperative mortality of 17%, while it decreased to 7% among the 27 patients studied by Pupka et al. 16 In both reports, the number of revision procedures is not explicit.
As for rifampicin-soaked grafts, Oderich et al. 7 reported an early mortality rate of only 8%, without further mention of the reintervention rate. Ehsan and Gibbons, 17 who used autologous veins, report a mortality rate of 5% for aortic reconstructions (n ¼ 16) and extra-aortic reconstructions. However, venous reconstruction is unsuitable for the emergent situation. 18 Interestingly, O'Connor et al. 19 calculated the combined mean rate of adverse events (mortality, amputation, reinfection). The event rate was 0.16 for extra-anatomical bypass, 0.07 for rifampicin-coated prosthesis, 0.09 for cryopreserved allografts, and 0.10 for veins. 19 
Cryopreservation method
Two cryopreservation protocols (À80 C and À150 C) were used. All allografts that had been cryopreserved at À150 C were either harvested before 2002 or imported from other tissue banks that used this protocol, with no expiration date. Starting from 2002, all grafts preserved at the tissue bank of the Henri Mondor University Hospital were stored at À80
C. The use of a À80 C freezing protocol was supported by the occurrence of allograft fractures after cryopreservation using nitrogen vapor at À150 C 20e22 and lesions of extracellular matrix during manipulations in cold nitrogen. 23 In addition, graft preservation at À80 C resulted in no difference in the structural or mechanical properties of rabbit carotids. 24 In clinical terms, Castier et al. 25 used human allografts preserved at À80 C in peripheral reconstructions, and did not report any allograft thrombosis or disruption with a mean follow-up of 34 months. In the series 61% of patients received grafts that had been cryopreserved at À80
C. The cryopreservation protocol did not have a significant influence on early mortality (p ¼ .76) or postoperative complication rate (p ¼ .87) The relationship between cryopreservation method and the occurrence of graft rupture or thrombosis was tested, and no difference was found between the protocols. This relationship could not be reliably assessed, as the study of factors associated with graft-related complications was affected by the fact that early mortality might have prevented the detection of these complications. Knowing that grafts preserved at À80
C were meant to be used within 2 years, we studied the duration of cryopreservation and found that grafts stored at À80 C were most frequently used within 6 months, as median graft age at use was 4.7 months; however, it was 18.5 months for the allografts kept at À150 C. After performing statistical analysis, the age of allograft was found to be a predictive factor in the univariate analysis for the occurrence of death or postoperative complications.
CONCLUSION
Unsatisfactory results for the use of cryopreserved allografts during in situ reconstruction of infected aortic aneurysms or grafts were observed. These results are difficult to interpret when compared with other series of similar populations and clinical and procedural data. The main obstacle appears to be the rate of early graft-related complications. The reinfection and limb salvage rates were satisfactory. Age, chronic renal disease, coronary disease, prosthetic infections, and urgent procedures were independent prognostic factors for postoperative mortality.
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